Idiopathic Thrombocytopenic Purpura Therapeutics Market To Reach $914.9 Million By 2030

Idiopathic Thrombocytopenic Purpura Therapeutics Market Growth & Trends

The global idiopathic thrombocytopenic purpura therapeutics market is expected to reach USD 914.9 million by 2030, expanding at a CAGR of 5.0% from 2023 to 2030, according to a new report by Grand View Research, Inc.  Rising R&D leading to the introduction of new drugs for IVIG and TPO-RA classes is expected to propel growth over the forecast period. In addition, government regulation such as the Orphan Drug Act in the United States with an aim to encourage new product development is projected to fuel growth.

The industry is characterized by a rising demand for combination therapies as they exhibit higher efficiency as compared to other treatments. Moreover, they are cost-efficient and help curb side effects associated with individual therapeutic classes. Some of the major combination therapies are dexamethasone and rituximab, dexamethasone and TPO-RA, IVIG, and corticosteroids. Splenectomy, the procedure to remove the spleen is aimed at reducing the amount of anti-platelet antibodies, is expected to fuel demand. Corticosteroids are regularly used in idiopathic thrombocytopenic purpura treatment. Since corticosteroid are considered to be the first line of therapy for patients suffering from ITP, the usage rates of corticosteroid are very high. 

 Request a free sample copy or view report summary: Idiopathic Thrombocytopenic Purpura Therapeutics Market Report

Idiopathic Thrombocytopenic Purpura Therapeutics Market Report Highlights 

• TPO-RA is likely to witness substantial growth, growing at a CAGR of over 6.6% from 2023 to 2030 owing to high response rates exhibited by patients administered with Eltrombopag and Romiplostim. Moreover, demand for TPO-RA is expected to increase due to the commercialization of Avatrombopag in 2015. In addition, the ability of TPO-RA to cater to splenectomized patients witnessing relapses is expected fuel demand over the next six years.

• North America dominated the market and accounted for the largest revenue share of 39.9% in 2022.

• Asia Pacific is expected to grow at the fastest CAGR of 6.2% over the forecast period.

• Asia Pacific is expected to experience substantial growth over the next six years, owing to the presence of favorable government initiatives, and sophisticated healthcare infrastructure in Australia and Japan. In addition, the presence of vast untapped opportunities in emerging markets such as China and India is expected to propel growth.

Idiopathic Thrombocytopenic Purpura Therapeutics Market Segmentation

Grand View Research has segmented the global idiopathic thrombocytopenic purpura therapeutics market based on disease type, product, and region:

Idiopathic Thrombocytopenic Purpura Therapeutics Disease Type Outlook (Revenue in USD Million, 2018 - 2030)

• Acute ITP

• Chronic

• Others

Idiopathic Thrombocytopenic Purpura Therapeutics Product Outlook (Revenue in USD Million, 2018 - 2030)

• Corticosteroids

• IVIG

• Anti-D Immunoglobulins

• TPO-RA

• Others

Idiopathic Thrombocytopenic Purpura Therapeutics Regional Outlook (Revenue in USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • Thailand

  • South Korea

• Latin America

  • Brazil

  • Mexico

  • Argentina

• Middle East and Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players of Idiopathic Thrombocytopenic Purpura Therapeutics Market

• Amgen Inc.

• F. Hoffmann-La Roche Ltd

• Grifols, S.A.

• GSK plc.

• Shangxian Minimal Invassive Inc.

• INTROMEDIC

• Medtronic

• FUJIFILM Holdings Corporation

• Olympus Corporation

• JINSHAN Science & Technology (Group) Co., Ltd.